Partenariat

Articles

• Vect-Horus Enters a CNS-Focused Research Collaboration with OliX Pharmaceuticals
  3 February, by Emmanuelle BETTENDORF

  We are delighted to announce we have entered into a Material Transfer and Evaluation Agreement with OliX Pharmaceuticals, a leading developer of RNAi therapeutics, to initiate a collaboration focused on siRNA delivery for central nervous system (CNS) disorders.
  “We are extremely pleased to partner with OliX. This collaboration underscores Vect-Horus’ leadership in BBB technology and its commitment to advancing oligonucleotide therapeutics in CNS diseases through strategic partnerships with (…)

• Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases
  30 January 2024, by Emmanuelle BETTENDORF

  Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Ionis Pharmaceuticals, Inc. (Nasdaq: IONS). The agreement provides Ionis with a worldwide, exclusive license for a specified number of targets using Vect-Horus’ platform technology ”VECTrans” for systemic delivery of RNA-targeted therapeutics that (…)

• RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for GBM and PDAC
  19 September 2025, by Emmanuelle BETTENDORF

  Together with our partner Radiomedix, Inc. , we have successfully dosed the first patient in an exploratory Investigational New Drug study evaluating the diagnostic 203Pb-RMX-VH-PIB in Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC).
  “The initiation of this clinical trial is an important milestone for Vect-Horus and demonstrates continuing progress in the collaboration with our partner RadioMedix,” says Alexandre Tokay, CEO of Vect-Horus.
  “We are looking forward (…)

• Vect-Horus and Cerimed announce collaboration to support the development of its theragnostic agents
  17 November 2020, by Elodie DORMES

  Vect-Horus is co-developing with Radiomedix one agent which will enter clinical trials in 2021 for the diagnosis of glioblastoma.
  With Cerimed, Vect-Horus also pursues the investigations on its other theragnostic candidates targeting the Low-Density Lipoprotein Receptor, which has been shown to be expressed at high levels in some tumours, including pancreatic tumours.

• Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
  11 July 2025, by Emmanuelle BETTENDORF

  We are proud and excited to announce a new strategic research collaboration with Secarna Pharmaceuticals!
  The partnership will focus on developing RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS), combining our delivery technology platform, VECTrans®, with Secarna’s proprietary OligoCreator® oligonucleotide discovery platform.
  The combination of these two technologies will expand Secarna’s targeted (…)

• Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases
  28 January 2019, by Jonathan NOWAK

  The partnership will develop new molecules for the treatment of brain diseases
  Vect-Horus, a French company specialized in the development of vector molecules for the central nervous system, announces today it has signed a scientific collaboration agreement with Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM). The financial terms of the deal have not been disclosed.
  This agreement is part of Vect-Horus’ strategy to leverage (…)

• Vect-Horus and RadioMedix announce the signing of a LOI to co-develop a Vect-Horus’ radio-theranostic agent for Glioblastoma
  6 March 2019, by Jonathan NOWAK

  Marseille, France- Houston - March 5, 2019 - Vect-Horus and RadioMedix announced today the signing of a Letter of Intent (LOI) to establish an agreement for the co-development of a Vect-Horus theranostic agent for the diagnostic and radiotherapy of Glioblastoma Multiforme (GBM) of the brain.
  This partnership will marry the expertise of Vect-Horus in targeting tumors with its technology VECTrans® and the know-how of RadioMedix in developing and conducting pre-clinical evaluation and (…)

• Vect-Horus announces agreement with Johnson&Johnson Innovation
  18 January 2019, by Jonathan NOWAK

  Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

• Vect-Horus announces the signing of a scientific collaboration agreement with SERVIER
  28 January 2019, by Jonathan NOWAK

  The two companies intend to enter in a collaboration agreement to develop new therapeutic molecules in the field of central nervous system (CNS) diseases
  VECT-HORUS, a biotechnology company that designs and develops peptide vectors that facilitate the delivery of drugs or imaging agents, notably in the brain, is announcing today the signing of a scientific collaboration agreement with SERVIER. The companies did not disclose the financial terms of this agreement. This collaboration is part (…)

• Relocation of the company to support its development
  1 October 2019, by Elodie DORMES

  Relocation of Vect-Horus in medical faculty of the La Timone campus to maintain strong collaborative working environment with its historical partners and support its development.